Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Détail de l'auteur
Auteur Daniela TROPEA |
Documents disponibles écrits par cet auteur (2)
Faire une suggestion Affiner la recherche
IGF1 as a Potential Treatment for Rett Syndrome: Safety Assessment in Six Rett Patients / Giorgio PINI in Autism Research and Treatment, (April 2012)
[article]
Titre : IGF1 as a Potential Treatment for Rett Syndrome: Safety Assessment in Six Rett Patients Type de document : Texte imprimé et/ou numérique Auteurs : Giorgio PINI, Auteur ; Maria Flora SCUSA, Auteur ; Laura CONGIU, Auteur ; Alberto BENINCASA, Auteur ; Paolina MORESCALCHI, Auteur ; Ilaria BOTTIGLIONI, Auteur ; Pietro DI MARCO, Auteur ; Paolo BORELLI, Auteur ; Ubaldo BONUCCELLI, Auteur ; Andrea DELLA-CHIESA, Auteur ; Adriele PRINA-MELLO, Auteur ; Daniela TROPEA, Auteur Année de publication : 2012 Article en page(s) : 14 p. Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Rett syndrome (RTT) is a devastating neurodevelopmental disorder that affects one in ten thousand girls and has no cure. The majority of RTT patients display mutations in the gene that codes for the methyl-CpG-binding protein 2 (MeCP2). Clinical observations and neurobiological analysis of mouse models suggest that defects in the expression of MeCP2 protein compromise the development of the central nervous system, especially synaptic and circuit maturation. Thus, agents that promote brain development and synaptic function, such as insulin-like growth factor 1 (IGF1), are good candidates for ameliorating the symptoms of RTT. IGF1 and its active peptide, (1–3) IGF1, cross the blood brain barrier, and (1–3) IGF1 ameliorates the symptoms of RTT in a mouse model of the disease; therefore they are ideal treatments for neurodevelopmental disorders, including RTT. We performed a pilot study to establish whether there are major risks associated with IGF1 administration in RTT patients. Six young girls with classic RTT received IGF1 subcutaneous injections twice a day for six months, and they were regularly monitored by their primary care physicians and by the unit for RTT in Versilia Hospital (Italy). This study shows that there are no risks associated with IGF1 administration. En ligne : http://dx.doi.org/10.1155/2012/679801 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=178
in Autism Research and Treatment > (April 2012) . - 14 p.[article] IGF1 as a Potential Treatment for Rett Syndrome: Safety Assessment in Six Rett Patients [Texte imprimé et/ou numérique] / Giorgio PINI, Auteur ; Maria Flora SCUSA, Auteur ; Laura CONGIU, Auteur ; Alberto BENINCASA, Auteur ; Paolina MORESCALCHI, Auteur ; Ilaria BOTTIGLIONI, Auteur ; Pietro DI MARCO, Auteur ; Paolo BORELLI, Auteur ; Ubaldo BONUCCELLI, Auteur ; Andrea DELLA-CHIESA, Auteur ; Adriele PRINA-MELLO, Auteur ; Daniela TROPEA, Auteur . - 2012 . - 14 p.
Langues : Anglais (eng)
in Autism Research and Treatment > (April 2012) . - 14 p.
Index. décimale : PER Périodiques Résumé : Rett syndrome (RTT) is a devastating neurodevelopmental disorder that affects one in ten thousand girls and has no cure. The majority of RTT patients display mutations in the gene that codes for the methyl-CpG-binding protein 2 (MeCP2). Clinical observations and neurobiological analysis of mouse models suggest that defects in the expression of MeCP2 protein compromise the development of the central nervous system, especially synaptic and circuit maturation. Thus, agents that promote brain development and synaptic function, such as insulin-like growth factor 1 (IGF1), are good candidates for ameliorating the symptoms of RTT. IGF1 and its active peptide, (1–3) IGF1, cross the blood brain barrier, and (1–3) IGF1 ameliorates the symptoms of RTT in a mouse model of the disease; therefore they are ideal treatments for neurodevelopmental disorders, including RTT. We performed a pilot study to establish whether there are major risks associated with IGF1 administration in RTT patients. Six young girls with classic RTT received IGF1 subcutaneous injections twice a day for six months, and they were regularly monitored by their primary care physicians and by the unit for RTT in Versilia Hospital (Italy). This study shows that there are no risks associated with IGF1 administration. En ligne : http://dx.doi.org/10.1155/2012/679801 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=178 Progress Toward Therapies and Interventions for Neurodevelopmental Disorders / Ayokunmi AJETUNMOBI
Titre : Progress Toward Therapies and Interventions for Neurodevelopmental Disorders Type de document : Texte imprimé et/ou numérique Auteurs : Ayokunmi AJETUNMOBI, Auteur ; Daniela TROPEA, Auteur Année de publication : 2015 Importance : p.319-344 Langues : Anglais (eng) Index. décimale : SCI-B SCI-B - Génétique Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=400 Progress Toward Therapies and Interventions for Neurodevelopmental Disorders [Texte imprimé et/ou numérique] / Ayokunmi AJETUNMOBI, Auteur ; Daniela TROPEA, Auteur . - 2015 . - p.319-344.
Langues : Anglais (eng)
Index. décimale : SCI-B SCI-B - Génétique Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=400 Exemplaires
Code-barres Cote Support Localisation Section Disponibilité aucun exemplaire